4basebio PLC
4BB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 94% | 84.5% | 22.4% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | -£0 | £0 | £0 |
| % Margin | 10.7% | -4.3% | 72% | 66.8% |
| R&D Expenses | -£0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | -£0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -701.1% | -1,794.4% | -1,768% | -1,778.4% |
| Other Income/Exp. Net | £0 | £0 | -£0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | £0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -664.7% | -1,091.7% | -1,746.3% | -1,533.6% |
| EPS | -0.5 | -0.51 | -0.45 | -0.33 |
| % Growth | 2% | -13.3% | -36.4% | – |
| EPS Diluted | -0.5 | -0.51 | -0.45 | -0.33 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -615.9% | -1,314.4% | -1,667.1% | -1,530.6% |